Cargando…

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

Ribonucleotide reductase subunits M1 (RRM1) and M2 (RRM2) are involved in the metabolism of gemcitabine (2′,2′-difluorodeoxycytidine), which is used for the treatment of nonsmall cell lung cancer. The mRNA expression of RRM1 and RRM2 in tumours from lung adenocarcinoma patients treated with docetaxe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Souglakos, J, Boukovinas, I, Taron, M, Mendez, P, Mavroudis, D, Tripaki, M, Hatzidaki, D, Koutsopoulos, A, Stathopoulos, E, Georgoulias, V, Rosell, R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391126/ https://www.ncbi.nlm.nih.gov/pubmed/18414411 http://dx.doi.org/10.1038/sj.bjc.6604344

Ejemplares similares

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
por: Boukovinas, Ioannis, et al.
Publicado: (2008)

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)

Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
por: Xia, Guanggai, et al.
Publicado: (2017)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine
por: Aoyama, Toru, et al.
Publicado: (2017)

High Expression of Ribonucleotide Reductase Subunit M2 Correlates with Poor Prognosis of Hepatocellular Carcinoma
por: Lee, Boin, et al.
Publicado: (2014)

Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
por: Mazzu, Ying Z., et al.
Publicado: (2020)

Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers
por: Zhang, Hang, et al.
Publicado: (2014)

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer
por: Daskalaki, A, et al.
Publicado: (2009)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

Ribonucleotide Reductase Subunit M2 Can Be New Molecular Target and Prognostic Biomarker of Hepatocellular Carcinoma
por: Kim, Hee Yeon, et al.
Publicado: (2014)

Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma
por: Zou, Yun, et al.
Publicado: (2019)

Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells
por: Yang, Pei-Ming, et al.
Publicado: (2020)

A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors
por: Li, Yaqun, et al.
Publicado: (2022)

Regulatory Role of Ribonucleotide Reductase Subunit M2 in Hepatocyte Growth and Pathogenesis of Hepatitis C Virus
por: Kitab, Bouchra, et al.
Publicado: (2023)

Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
por: Tu, Min, et al.
Publicado: (2017)

Regulation of ribonucleotide reductase M2 expression by the upstream AUGs
por: Dong, Zizheng, et al.
Publicado: (2005)

Differential accumulation of ribonucleotide reductase subunits in clam oocytes: the large subunit is stored as a polypeptide, the small subunit as untranslated mRNA
Publicado: (1986)

Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells
por: Wang, Nan, et al.
Publicado: (2018)

Ubiquitination and Degradation of Ribonucleotide Reductase M1 by the Polycomb Group Proteins RNF2 and Bmi1 and Cellular Response to Gemcitabine
por: Zhang, Yingtao, et al.
Publicado: (2014)

mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer()()
por: Tian, Ling, et al.
Publicado: (2021)

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
por: Vamvakas, Lambros, et al.
Publicado: (2014)

Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers
por: Liu, Xiyong, et al.
Publicado: (2013)

Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production
por: Perrault, Ella N., et al.
Publicado: (2023)

P53 suppresses ribonucleotide reductase via inhibiting mTORC1
por: He, Zhengfu, et al.
Publicado: (2017)

Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer
por: Wang, Qinchuan, et al.
Publicado: (2013)

Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib-based therapy
por: Liu, Chunshui, et al.
Publicado: (2019)

CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer
por: Fang, Zejun, et al.
Publicado: (2016)

Hug1 is an intrinsically disordered protein that inhibits ribonucleotide reductase activity by directly binding Rnr2 subunit
por: Meurisse, Julie, et al.
Publicado: (2014)

Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide
por: Karachaliou, Niki, et al.
Publicado: (2013)

Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy
por: Wijerathna, Sanath R., et al.
Publicado: (2011)

Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer
por: Yin, Xin, et al.
Publicado: (2023)

Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse
por: Brown, Anthony, et al.
Publicado: (2023)

The Clinical and Prognostic Significance of Ribonucleotide Reductase Subunits RRM1 and RRM2 mRNA Levels in Patients with Chronic Lymphocytic Leukemia
por: Chatzidavid, Sevastianos, et al.
Publicado: (2023)

Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication
por: Foskolou, Iosifina P., et al.
Publicado: (2017)

Ribonucleotide reductase M2B in the myofibers modulates stem cell fate in skeletal muscle
por: Chen, Wan-Jing, et al.
Publicado: (2022)

Screening of traditional Chinese medicine monomers as ribonucleotide reductase M2 inhibitors for tumor treatment
por: Qin, Ya-Ya, et al.
Publicado: (2022)

Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer
por: Zuo, Zanwen, et al.
Publicado: (2022)

Ribonucleotide Reductase Subunit M2 Predicts Survival in Subgroups of Patients with Non-Small Cell Lung Carcinoma: Effects of Gender and Smoking Status
por: Mah, Vei, et al.
Publicado: (2015)

Ribonucleotide reductase subunit M2 promotes proliferation and epithelial–mesenchymal transition via the JAK2/STAT3 signaling pathway in retinoblastoma
por: Yang, Min, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a1qrud051ekphrvfsrn1dleg8e